Rheumatology Journals
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Rheumatology
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
rheumatoid arthritis  rheumatoid arthritis
lupus  lupus
polymyalgia  polymyalgia
sjogrens  sjogrens
fibromyalgia  fibromyalgia
amyloidosis  amyloidosis
vasculitis  vasculitis
urate  urate
raynauds  raynauds
myositis  myositis
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment
Kim S et al. – Findings suggest that aggressive treatment of juvenile dermatomyositis (DM) aimed at achieving rapid, complete control of muscle weakness and inflammation improves outcomes and reduces disease-related complications, leading into prolonged, medication-free remission within a median of 38 months from the time of diagnosis.

Methods
  • An assessment of the time needed to achieve sustained, medication-free remission in pts with juvenile DM receiving a stepwise, aggressive treatment protocol
  • 49 children with juvenile DM received standardized therapy with steroids and methotrexate
  • If a pt's strength or muscle enzyme levels did not normalize with this initial therapy, additional medications were added in rapid succession to the treatment regimen
  • Primary outcome measure: time to complete remission
  • Additional outcome measures: onset of calcinosis, effect of treatment on height, and complications resulting from medications
Results
  • 49 pts were followed up for a mean of 48 mo
  • All but 1 patient received ≥2 medications simultaneously
  • Transient localized calcifications occurred in 8%, and 4% additional had persistent calcinosis
  • Despite the aggressive therapy, complications associated with treatment were mild and were primarily attributable to steroids
  • No persistent effect on longitudinal growth was observed
  • A complete, medication-free remission was achieved in 28 pts
  • Median time to achievement of CR was 38 mo
  • None of these pts experienced a disease flare that required resumption of medications during the subsequent period of observation
[more...]
Sponsor

Read a Different Specialty

General Rheumatology Articles
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

General Rheumatology Articles
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.